Quantification of Measurable Residual Disease Detection by Next-Generation Sequencing –Based Clonality Testing in B-Cell and Plasma Cell Neoplasms

Next-generation sequencing (NGS)-based measurable residual disease (MRD) monitoring in post-treatment settings can be crucial for relapse risk stratification in patients with B-cell and plasma cell neoplasms. Prior studies have focused on validation of various technical aspects of the MRD assays, but more studies are warranted to establish the performance characteristics and enable standardization and broad utilization in routine clinical practice. Here, the authors describe an NGS-based IGH MRD quantification assay, incorporating a spike-in calibrator for monitoring B-cell and plasma cell neoplasms based on their unique IGH rearrangement status.

Source: Journal of Molecular Diagnostics - December 14, 2023 Category: Pathology Authors: Ying Liu, Caleb Ho, Wayne Yu, Ying Huang, Jeffrey Miller, Qi Gao, Mustafa Syed, Yuanyuan Ma, Meiyi Wang, Lidia Maciag, Kseniya Petrova-Drus, Menglei Zhu, JinJuan Yao, Chad Vanderbilt, Benjamin Durham, Jamal Benhamida, Mark D. Ewalt, Ahmet Dogan, Mikhail R Tags: Regular article Source Type: research